Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Price Zscore is at a recent 2 week high. A recent high ZScore means price movement is accelerating at a record speed.
- RSI is at a high level of 77. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
| MarketCap | 408.2M |
|---|---|
| PE Ratio | |
| PEG Ratio | -3.4 |
| P/B | 3.1 |
| P/S (ttm) | 42.6 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 1% |
| Held by Institutions % | 63% |
| 1 Day Vol Adjusted Return | 1.6 |
| 1 Month Vol Adjusted Return | 10.8 |
| 3 Month Vol Adjusted Return | 3.7 |
| 6 Month Vol Adjusted Return | 0.3 |
| 20 Days SMA Price ZScore | 3.0 |
| 50 Days SMA Price ZScore | 4.0 |
| 12 -26 Days PPO | 5.2 |
| 1 Month Average Short Volume Ratio | 32.6 |
| 1 Day Volume Change ZScore | 0.9 |
| 1 Month Daily Vol | 3.6 |
Stock news
MeiraGTx Holdings plc (NASDAQ: MGTX) announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX), dry mouth symptoms. Clinically meaningful improvements in xerostomia symptoms were reported consistently across two validated PROs assessing xerostomia symptom severity. Meaningful increases in whole saliva flow rates were observed post-treatment, providing objective evidence of the biological activity of AAV2-hAQP1 treatment.
Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NE
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So take a...
LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present clinical data from the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 13, 2022, at 8:00 a.m. ET. The Phase 1 AQUAx conference call will also include a clinical program update for product candidate
LONDON and NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Piper Sandler 34th Annual Healthcare Conference (New York) Fireside Chat: Tuesday, November 29, 2022 at 8:30 a.m. ET Evercore ISI 5th Annual HealthCONx Conference (Virtual) Fireside Chat: Thursday, Decemb
MeiraGTx Holdings ( NASDAQ:MGTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.82m (down 31% from 3Q...
Market forces rained on the parade of MeiraGTx Holdings plc ( NASDAQ:MGTX ) shareholders today, when the analysts...
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
-- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Now Dosing Patients in Phase 1 Trial Evaluating AAV-GAD Gene Therapy for Parkinson’s Disease -- Received $25.0 Million Investment from Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), the Investment Arm of Johnson and Johnson -- Company to Provide Clinical Program Update for the Phase 1 AQUAx Trial of AAV-hAQP1 for the Treatment of Gra
Every investor in MeiraGTx Holdings plc ( NASDAQ:MGTX ) should be aware of the most powerful shareholder groups. With...